VSY Biotechnology's Sinusoidal Trifocal IOL Technology Receives Japanese Approval
核心洞察
VSY Biotechnology GmbH (搜索)'s Sinusoidal Trifocal Technology® has received official approval in Japan, marking the company's entry into the Japanese ophthalmic market.
The innovative IOL technology eliminates traditional challenges of light loss, light scatter, and poor night vision associated with sawtooth technology used in conventional trifocal lenses.
WAKAMOTO PHARMACEUTICAL CO., LTD will serve as the official distributor in Japan, with non-toric lenses already launching in the market.
VSY Biotechnology GmbH (搜索) has achieved regulatory approval in Japan for its Sinusoidal Trifocal Technology®, marking a significant milestone in the company's international expansion. The German-based company's innovative intraocular lens (IOL) technology is now available to Japanese patients, with non-toric lenses already launching in the market and toric versions to follow.
Advanced Technology Addresses Market Limitations
The Sinusoidal Trifocal Technology® represents a significant advancement over existing IOL solutions. Traditional trifocal, hybrid trifocal, and polyfocal lenses currently available on the market often present challenges such as light loss, light scatter, and poor night vision due to sawtooth technology. VSY Biotechnology's innovative approach has eliminated these issues through its patented sinusoidal design.
The technology provides superior visual performance at near, intermediate, and distance ranges for both refractive and cataract patients. Notably, side effects such as halos and glare, which are commonly associated with traditional multifocal IOLs, are not observed with this new generation of lenses.
Strategic Partnership for Japanese Market Entry
WAKAMOTO PHARMACEUTICAL CO., LTD, a well-established pharmaceutical company, will serve as VSY Biotechnology's official distributor in Japan. The partnership was formalized following a recent visit by WAKAMOTO executives to VSY Biotechnology's headquarters in Leinfelden-Echterdingen, Germany.
CEO Arata Igarashi of WAKAMOTO PHARMACEUTICAL expressed his pride and excitement in representing VSY Biotechnology in Japan. The collaboration represents a strategic alliance between the German biotechnology innovator and the established Japanese pharmaceutical distributor.
Clinical Impact and Market Positioning
Dr. Christian Bach, Managing Director of VSY Biotechnology GmbH (搜索), emphasized the company's confidence in achieving significant success in the Japanese market through their collaboration with WAKAMOTO. He expressed satisfaction in bringing Sinusoidal Trifocal Technology® to patients in Japan, highlighting the clinical benefits the technology offers to both refractive and cataract patients.
The approval encompasses both non-toric and toric IOL variants, providing comprehensive solutions for patients with varying degrees of astigmatism. This broad product portfolio positions VSY Biotechnology to address diverse patient needs in the Japanese ophthalmic market.